279 In the index

Empagliflozin EMPA

An FDA-approved diabetes drug (Jardiance) that also helps with heart failure and kidney disease. Landmark studies show it provides strong heart and kidney protection beyond just controlling blood sugar, making it one of the better-proven drugs in its category.

Also known as Jardiance, BI 10773, Empagliflozina, Empagliflozine, HDC1R2M35U, CHEBI:82720, GLYXAMBI COMPONENT EMPAGLIFLOZIN

Effects Longevity Lose fat

Routes Oral

Legal status Prescription drug

WADA Not listed

3D Molecular Structure of C₂₃H₂₇ClO₇

Drag to rotate · scroll to zoom

Chemistry

Formula: C23H27ClO7
Molar mass: 450.9
CAS: 864070-44-0
PubChem CID: 11949646
IUPAC name: (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
InChIKey: OBWASQILIWPZMG-QZMOQZSNSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 10 mg

Reported range 10-25 mg/day

Route Oral

Frequency Once daily

Duration Chronic/ongoing (as prescribed)

FDA-approved SGLT2 inhibitor (Jardiance) for type 2 diabetes, heart failure, and chronic kidney disease.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.